Uber Technologies Inc. reported weaker-than-expected fourth-quarter earnings and operating income, overshadowing steady bookings growth. Shares declined in premarket trading on Wednesday.

The weight-loss drugmaker's Wegovy and Ozempic are among the most closely watched new medications in recent history, but face serious competition from Eli Lilly’s Zepbound and Mounjaro.